Volume 372, Issue 9647, Pages 1385-1393 (October 2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Prof Anne Katrin Sjølie, DrSci, Prof Ronald Klein, MD, Prof Massimo Porta, PhD, Prof Trevor Orchard, MB, Prof John Fuller, FRCP, Prof Hans Henrik Parving, DrSci, Prof Rudy Bilous, FRCP, Prof Nish Chaturvedi, MD The Lancet Volume 372, Issue 9647, Pages 1385-1393 (October 2008) DOI: 10.1016/S0140-6736(08)61411-7 Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile The Lancet 2008 372, 1385-1393DOI: (10.1016/S0140-6736(08)61411-7) Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 2 Cumulative proportion of patients with progression of retinopathy by treatment allocation The Lancet 2008 372, 1385-1393DOI: (10.1016/S0140-6736(08)61411-7) Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 3 Distribution of changes in ETDRS level during study, by treatment group The Lancet 2008 372, 1385-1393DOI: (10.1016/S0140-6736(08)61411-7) Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 4 Cumulative proportion of patients with regression of retinopathy, by treatment group The Lancet 2008 372, 1385-1393DOI: (10.1016/S0140-6736(08)61411-7) Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 5 Cumulative proportion of patients with regression of retinopathy, grouped by retinopathy level at baseline (A) Microaneurysms only. (B) Mild non-proliferative diabetic retinopathy. (C) Moderate to moderately severe retinopathy. The Lancet 2008 372, 1385-1393DOI: (10.1016/S0140-6736(08)61411-7) Copyright © 2008 Elsevier Ltd Terms and Conditions